Edition:
United States

Oxford Immunotec Global PLC (OXFD.OQ)

OXFD.OQ on NASDAQ Stock Exchange Global Market

16.37USD
4:00pm EDT
Change (% chg)

$-0.61 (-3.59%)
Prev Close
$16.98
Open
$16.95
Day's High
$17.11
Day's Low
$16.30
Volume
43,000
Avg. Vol
38,774
52-wk High
$19.10
52-wk Low
$10.26

Latest Key Developments (Source: Significant Developments)

U.S. FDA Approves First Tests To Screen For Tickborne Parasite In Whole Blood & Plasma
Tuesday, 6 Mar 2018 06:18pm EST 

March 6 (Reuters) - U.S. Food and Drug Administration::U.S. FDA SAYS APPROVED THE IMUGEN BABESIA MICROTI ARRAYED FLUORESCENT IMMUNOASSAY FOR DETECTING ANTIBODIES TO BABESIA MICROTI IN HUMAN PLASMA SAMPLES.U.S. FDA SAYS APPROVED THE IMUGEN BABESIA MICROTI NUCLEIC ACID TEST FOR DETECTING B. MICROTI DNA IN HUMAN WHOLE BLOOD SAMPLES.U.S. FDA SAYS APPROVAL OF THE IMUGEN BABESIA MICROTI AFIA AND NAT TESTS WAS GRANTED TO OXFORD IMMUNOTEC INC.  Full Article

Oxford Immunotec Q4 Earnings Per Share $0.33
Tuesday, 27 Feb 2018 07:00am EST 

Feb 27 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 EARNINGS PER SHARE $0.33.Q4 REVENUE ROSE 6 PERCENT TO $25 MILLION.SEES FY 2018 REVENUE $112 MILLION TO $118 MILLION.  Full Article

James Flynn Reports 5.1 Pct Passive Stake In Oxford Immunotec Global Plc As Of Jan 22
Thursday, 1 Feb 2018 05:18pm EST 

Feb 1 (Reuters) - Oxford Immunotec Global Plc ::JAMES FLYNN REPORTS 5.1 PERCENT PASSIVE STAKE IN OXFORD IMMUNOTEC GLOBAL PLC AS OF JANUARY 22 - SEC FILING.  Full Article

Oxford Immunotec Announces Preliminary Revenue For Q4
Monday, 8 Jan 2018 08:30am EST 

Jan 8 (Reuters) - Oxford Immunotec Global Plc ::FY2017 REVENUE VIEW $104.1 MILLION -- THOMSON REUTERS I/B/E/S.OXFORD IMMUNOTEC ANNOUNCES PRELIMINARY REVENUE FOR FOURTH QUARTER AND FULL YEAR 2017.SEES FY 2017 REVENUE $103 MILLION TO $103.5 MILLION.SEES Q4 2017 REVENUE $24.9 MILLION TO $25.4 MILLION.Q4 REVENUE VIEW $26.1 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Oxford Immunotec And Qiagen Reached A Settlement In Lawsuit
Friday, 15 Dec 2017 04:04pm EST 

Dec 15 (Reuters) - Oxford Immunotec Global Plc ::OXFORD IMMUNOTEC GLOBAL - CO, QIAGEN REACHED A SETTLEMENT IN LAWSUIT IN U.S. COURT ALLEGING PATENT INFRINGEMENT IN RELATION TO QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL - UNDER TERMS OF AGREEMENT, ALL PENDING CLAIMS BETWEEN OXFORD, QIAGEN AND CO-DEFENDANTS HAVE BEEN RESOLVED.OXFORD IMMUNOTEC GLOBAL - CO GRANTED QIAGEN ROYALTY-FREE, NON-EXCLUSIVE LICENSE THAT EXTENDS TO ALL CURRENT AND FUTURE CUSTOMERS OF QIAGEN'S PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - PATENT INFRINGEMENT IS IN RELATION TO QIAGEN'S QUANTIFERON-TB GOLD AND QUANTIFERON-TB GOLD PLUS PRODUCTS.OXFORD IMMUNOTEC GLOBAL PLC - OXFORD GRANTED QIAGEN A ROYALTY-FREE, NON-EXCLUSIVE LICENSE IN EXCHANGE FOR A ONE-TIME, LUMP-SUM PAYMENT OF $27.5 MILLION.  Full Article

Oxford Immunotec Global Plc says unit entered into a 2nd amendment to purchase agreement with Mabtech AB​
Tuesday, 21 Nov 2017 05:06pm EST 

Nov 21 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc - ‍on Nov 17, unit entered into a second amendment to purchase agreement with Mabtech AB​.Oxford Immunotec Global says ‍second amendment extends term of agreement until December 31, 2023 & establishes pricing - SEC Filing​.  Full Article

Oxford Immunotec Global Q3 loss per share $0.70
Tuesday, 31 Oct 2017 07:00am EDT 

Oct 31 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec reports third quarter 2017 financial results.Q3 loss per share $0.70.Sees Q4 2017 revenue $25.4 million to $26.4 million.Q3 revenue $30.4 million versus I/B/E/S view $30 million.Q3 earnings per share view $-0.24 -- Thomson Reuters I/B/E/S.Sees FY 2017 revenue $103.5 million to $104.5 million.FY2017 revenue view $104.6 million -- Thomson Reuters I/B/E/S.  Full Article

Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares
Tuesday, 15 Aug 2017 09:00am EDT 

Aug 15 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc announces pricing of underwritten public offering of ordinary shares.Oxford Immunotec Global Plc - ‍pricing of its previously announced underwritten public offering of 2.5 million ordinary shares​.Oxford Immunotec Global Plc - ‍aggregate gross proceeds from offering to Oxford Immunotec will be $40.125 million​.  Full Article

Oxford Immunotec Global announces agreement to sell 2.5 mln ordinary shares
Monday, 14 Aug 2017 04:20pm EDT 

Aug 14 (Reuters) - Oxford Immunotec Global Plc :Oxford Immunotec Global Plc announces agreement to sell 2,500,000 ordinary shares.Oxford Immunotec Global Plc - ‍ agreement to sell 2.5 million ordinary shares to Btig, Llc as underwriter in an underwritten public offering​.Oxford Immunotec Global Plc - ‍oxford immunotec intends to use net proceeds from offering for working capital and general corporate purposes​.  Full Article

Oxford Immunotec Q2 loss per share $0.74
Tuesday, 1 Aug 2017 07:00am EDT 

Aug 1 (Reuters) - Oxford Immunotec Global Plc :Oxford immunotec reports second quarter 2017 financial results.Q2 loss per share $0.74.Sees q3 2017 revenue $29.5 million to $30.5 million.Q2 revenue $26.1 million versus i/b/e/s view $25 million.Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S.Sees fy 2017 revenue $103 million to $106 million.  Full Article